SUNPHARMA: Sales rose 11.8%; India growth offset U.S. pressure from lenalidomide erosion and slower ILUMYA

What happened

Sun Pharmaceutical's second-quarter sales rose 11.8% and adjusted net profit reached INR 31,620 million. India and innovative medicines grew, while U.S. sales faced lenalidomide erosion and slower ILUMYA growth. The company maintained its FY27 guidance.

Confirmed

Global impact / market context

Sales growth shows the company can offset weaker U.S. revenue with India and innovative medicines. That mix shift matters because U.S. products face falling prices and slower growth, so earnings depend on whether domestic and new medicines can keep replacing lost U.S. sales.

Analyst inference

Investors often value drug makers on whether growth is durable, not just headline sales. Here growth came from India and innovative medicines, while two U.S. products weakened. Maintained guidance suggests management expects the current mix to hold, which supports profit visibility even as U.S. pressure continues.

Analyst inference

What to watch

1. Watch whether India and innovative medicines keep growing enough to offset lenalidomide erosion and slower ILUMYA growth in the U.S., since those two products are named as the weak spots in the results. Confirmed
2. The company should clarify how much of its sales growth came from India versus innovative medicines, so investors can judge which engine is replacing lost U.S. revenue. Proposed
3. Watch whether FY27 guidance stays unchanged next quarter; any cut would signal that U.S. price pressure from lenalidomide and slower ILUMYA is spreading faster than India growth can offset. Analyst inference

Evidence

• Original source link unavailable